@article{ac493b38bff74db29bdc9e937bed7e6c,
title = "Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses",
abstract = "Although antibodies that effectively neutralize a broad set of influenza viruses exist in the human antibody repertoire, they are rare. We used a single-cell screening technology to identify rare monoclonal antibodies (MAbs) that recognized a broad set of influenza B viruses (IBV). The screen yielded 23 MAbs with diverse germ line origins that recognized hemagglutinins (HAs) derived from influenza strains of both the Yamagata and Victoria lineages of IBV. Of the 23 MAbs, 3 exhibited low expression in a transient-transfection system, 4 were neutralizers that bound to the HA head region, 11 were stalk-binding nonneutralizers, and 5 were stalk-binding neutralizers, with 4 of these 5 having unique antibody sequences. Of these four unique stalk-binding neutralizing MAbs, all were broadly reactive and neutralizing against a panel of multiple strains spanning both IBV lineages as well as highly effective in treating lethal IBV infections in mice at both 24 and 72 h postinfection. The MAbs in this group were thermostable and bound different epitopes in the highly conserved HA stalk region. These characteristics suggest that these MAbs are suitable for consideration as candidates for clinical studies to address their effectiveness in the treatment of IBV-infected patients.",
keywords = "IBV, Influenza, Monoclonal antibodies",
author = "Adam Vigil and Angeles Est{\'e}lles and Kauvar, {Lawrence M.} and Johnson, {Scott K.} and Tripp, {Ralph A.} and Michael Wittekind",
note = "Funding Information: The studies were primarily funded by ContraFect Corporation, Inc. Partial funding was provided by grant 5R44AI106077-04 from the U.S. National Institute of Allergy and Infectious Diseases to Trellis Bioscience, LLC (principal investigator, L. M. Kauvar). The in vivo experiments at the University of Georgia (UGA) were funded through contracts with ContraFect and Trellis and with support through the Georgia Research Alliance. Funding Information: The studies were primarily funded by ContraFect Corporation, Inc. Partial funding was provided by grant 5R44AI106077-04 from the U.S. National Institute of Allergy and Infectious Diseases to Trellis Bioscience, LLC (principal investigator, L. M. Kauvar). The in vivo experiments at the University of Georgia (UGA) were funded through contracts with ContraFect and Trellis and with support through the Georgia Research Alliance. The investigators from UGA have no other financial interest in either ContraFect or Trellis. All other authors are or have been paid employees of either ContraFect or Trellis. ContraFect is the exclusive licensee to the MAbs discovered by Trellis described here. We thank Robert Stephenson, Keyi Liu, Reyna Simon, Da Ngyen, Jianzhong Zhang, Evelene Lomongsod, Robert Durso, Kathleen Provoncha, Natalia Frias-Staheli, Vanessa Guzman, and Nicholas Caliendo for technical support during the course of these studies and Steven Jones, Cara Cassino, Alena Jandourek, and Teresa Carabeo for critical reading of the manuscript. Publisher Copyright: Copyright {\textcopyright} 2018 Vigil et al.",
year = "2018",
month = may,
doi = "10.1128/AAC.02269-17",
language = "English",
volume = "62",
pages = "1--9",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",
}